Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models

Ovarian cancer (OVCA) inevitably acquires resistance to platinum chemotherapy and PARP inhibitors (PARPi). We show that acquisition of PARPi-resistance is accompanied by increased ATR-CHK1 activity and sensitivity to ATR inhibition (ATRi). However, PARPi-resistant cells are remarkably more sensitive...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Nat Commun
Main Authors: Kim, Hyoung, Xu, Haineng, George, Erin, Hallberg, Dorothy, Kumar, Sushil, Jagannathan, Veena, Medvedev, Sergey, Kinose, Yasuto, Devins, Kyle, Verma, Priyanka, Ly, Kevin, Wang, Yifan, Greenberg, Roger A., Schwartz, Lauren, Johnson, Neil, Scharpf, Robert B., Mills, Gordon B., Zhang, Rugang, Velculescu, Victor E., Brown, Eric J., Simpkins, Fiona
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2020
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7381609/
https://ncbi.nlm.nih.gov/pubmed/32709856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-17127-2
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki